LRMR · Larimar Therapeutics
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Three Bala Plaza East, Bala Cynwyd, PA, 19004, United States
Biotechnology
Healthcare
Market Cap
310.6M
52 Wk Range
$1.92 - $6.42
Previous Close
$2.99
Open
$2.95
Volume
1,405,031
Day Range
$2.93 - $3.35
Enterprise Value
190M
Cash
128.7M
Avg Qtr Burn
-31.19M
Insider Ownership
1.26%
Institutional Own.
N/A
Qtr Updated
Sep 30th 2026
